Mersana Acquisition: Biotech Trade Setups

Day One Biopharmaceuticals has agreed to acquire Mersana Therapeutics in a deal worth up to 285 million dollars, paying 25 dollars per share in cash plus potential milestone payments. That headline sent $MRSN up more than 200 percent, while $DAWN dropped as traders worried about execution risk and the size of the cheque.

In this episode, we break down what the deal means for antibody drug conjugate names, where the next takeover candidates might be hiding, and how traders can think about long and short trading ideas around this kind of biotech merger news.

WINNERS

ADC takeover targets and peers

Reason: The huge premium for $MRSN reminds the market that strategic buyers will still pay up for promising antibody drug conjugate pipelines. This can re rate other small oncology nam ...